9
Medscape: Analysis boosts Fluvoxamine for COVID, but what's the evidence?
April 14, 2022
A report published recently in JAMA Open Network finds there's a strong likelihood that the antidepressant fluvoxamine (Luvox) may moderately lower rates of hospitalization due to COVID-19 in unvaccinated patients. However, outside experts cited by Medscape differ over whether the evidence from just three studies is strong enough to warrant adding the drug to the COVID-19 armamentarium. One of those experts sources is Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine.